However, in our present study, at only 61.9%, the overall response to COVID-19 inactivated vaccine was suboptimal and significantly reduced patients suffering hematological malignancies than
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor